Uncommon Solid Pancreatic Neoplasm: The Role of New Modalities of Ultrasound Endoscopy

Cátia Leitão  Helena Ribeiro  João Pinto  Ana Caldeira  Eduardo Pereira
António Banhudo
Department of Gastroenterology, Amato-Lusitano Hospital, ULSCB, Castelo Branco, Portugal

Keywords
Undifferentiated carcinoma osteoclast-like cells · Endoscopic ultrasound · Real-time elastography · Contrast enhancement · Pancreas

Abstract
Undifferentiated carcinoma with osteoclast-like cells is a rare pancreatic neoplasm with unique ultrasound endoscopic features. A 59-year-old female presented with a 3-month history of weight loss. Abdominal computed tomography and endoscopic ultrasound showed a large pancreatic tumor with a heterogeneous echotexture and liver metastasis. Endoscopic ultrasound fine needle aspiration was used to establish the diagnosis. In this case report, we review the endoscopic, clinical, and pathological features of this type of tumor and describe for the first time the endoscopic features of real-time elastography and contrast enhancement. Real-time elastography revealed a heterogeneous predominantly blue pattern suggestive of pancreatic malignancy, and the contrast-enhanced endosonography showed a hypervascular mass and distinctive vascular (solid) and avascular (liquid/necrotic) components of the lesion, guiding the fine needle aspiration.
Introduction

Undifferentiated carcinoma with osteoclast-like cells (UCOC) accounts for less than 1% of exocrine pancreatic malignancies, with only few reported cases in the literature [1–6]. The true origin of these lesions remains unclear and difficult to evaluate given the rarity of this tumor [3, 4]. These lesions have a distinct appearance when imaged with endoscopic ultrasound (EUS), and they can be diagnosed via EUS-guided fine needle aspiration [5, 6].

In this case report, we aim to highlight unique ultrasound endoscopic findings of this type of tumor from two new advanced technologies – real-time elastography and contrast enhancement.

Case Report

A 59-year-old female was referred to the Gastroenterology Department with weight loss over 3 months and a large pancreatic mass detected on the abdominal computed tomography. There was no previous history of alcohol or tobacco use and no significant past medical or family history. On physical examination, her abdomen was slightly tender in the epigastric area. Laboratory tests revealed mild elevation of transaminases (AST 150 U/L and ALT 83 U/L; normal range, AST <59 U/L and ALT <72 U/L). Other biochemical indices were normal. Among the tumor markers examined, carbohydrate antigen 19-9 and carcinoembryonic antigen were increased to 700 U/mL (normal range, 0–37 U/mL) and 1,385 ng/mL (normal range, <5 ng/mL), respectively. Abdominal computed tomography showed a large mass in the pancreatic tail with a cyst-like low-density area and an area of necrosis and liver metastases. On EUS, the tumor was a large lesion in the pancreatic body and tail, with a mean diameter of 84 mm and a heterogeneous echotexture, with hypo- and anechoic areas (Fig. 1). Increased vascularity was assessed by power color Doppler ultrasound. Real-time elastography was used in order to assess the relative stiffness of tumor tissue compared to the surrounding pancreatic parenchyma; it showed a heterogeneous predominantly blue pattern, with slight green areas (Fig. 2). After baseline EUS examination, a bolus of 2.4 mL of SonoVue® (Bracco Imaging, Milan, Italy) was administered intravenously, and contrast-enhanced endosonography (CE-EUS) was performed according to the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines and recommendations on the clinical practice of Contrast Enhanced Ultrasound on nonhepatic applications [7]. CE-EUS revealed a hypervascularized tumor compared to the surrounding pancreatic parenchyma and discriminated an avascular central component of the lesion, corresponding to a necrotic area. Therefore, the use of CE-EUS allowed us to select the best areas to puncture, avoiding the necrotic area with great improvement of the diagnostic yield (Fig. 3). The tumor was sampled twice using a 22-gauge aspiration needle (Cook Medical Inc., Bloomington, IN, USA). Abundant specimens were obtained for cytological and histopathological examination. A part of the material was preserved for cell block.

Histological examination revealed undifferentiated pancreas carcinoma with admixture of osteoclastic-like multinucleated giant cells and atypical oval or polygonal mononuclear cells. The hematoxylin and eosin and CKAE1/AE3 immunohistochemical stain images showed glands invaded by inflammatory cells including osteoclast-like giant cells. Additional immunohistochemical study revealed positivity for vimentin and CD68 and keratin, favoring mesenchymal and epithelial origin (Fig. 4).

The patient underwent two cycles of gemcitabine (1,480 mg). Chemotherapy was stopped because of pancytopenia. The patient died 2 months after the diagnosis.

Discussion

Pancreatic giant cell tumors are rare tumors of debatable origin. There are three histopathological subtypes: osteoclast-like giant cell tumor, pleomorphic giant cell carcinoma, and mixed varieties [7]; however, since 2010, the World Health Organization has grouped them together as UCOC [8].

Pancreatic giant cell tumors have unique clinical and pathological characteristics. Similar to pancreatic adenocarcinoma, UCOC of the pancreas tend to occur in the...
elderly with similar prevalence in women and men [4]. Most patients present with epigastric pain, abdominal distension and jaundice related to malignant biliary obstruction. In this case, the patient presented only weight loss. The patient did not report any alcohol or tobacco use, and she had no history of pancreatitis, similar to the reports in the literature, suggesting that the risk factors may differ from those of pancreatic adenocarcinoma [6].

EUS is an indispensable method for detection, characterization, and differential diagnosis of solid pancreatic lesions [9]. EUS fine needle aspiration established the diagnosis in our case report. The EUS appearance was different from the typical adenocarcinoma. UCOC tended to be larger and appeared markedly heterogeneous with well-demarcated hyper- and hypoechoic areas closely opposed within the same lesion. Using advanced technologies such as real-time elastography and contrast enhancement, pancreatic ductal adenocarcinoma and other solid lesions (including rare neoplasms and benign lesions) may be distinguished [9, 10]. UCOC showed a heterogeneous predominantly blue pattern on real-time elastography, present mainly in pancreatic ma-

![Fig. 2. On real-time elastography, the tumor appeared with a heterogeneous predominantly blue pattern, with slight green areas.](image1)

![Fig. 3. Tumor was hypervascular compared with the surrounding pancreatic parenchyma, and an avascular central component of the lesion (liquid/necrotic) could be discriminated using contrast-enhanced endosonography.](image2)
Lignant tumors. UCOC was a hypervascular mass when compared to the surrounding parenchyma, in contrast to what is described for pancreatic adenocarcinoma [9, 10]. Other differential diagnoses to consider were neuroendocrine tumors and serous microcystic neoplasia as they typically appear as hyperenhancing masses in the arterial phase, like we described in our case [11]. To the best of our knowledge, this is the first case reported in the literature describing the endoscopic features of these new EUS techniques.

The prognosis in patients with UCOC appears similar to that seen in pancreatic adenocarcinoma overall [4]. It is possible that patients with pleomorphic mononuclear and multinucleated giant cells follow an aggressive course with early metastasis and poor prognosis, as was the case in our patient, who died 2 months after the diagnosis [4–6]. Unfortunately, due to the rarity of this neoplasm, there is a lack of large studies or individual experience concerning the management of this tumor.

**Statement of Ethics**

This study did not require informed consent or review/approval by the appropriate ethics committee.

**Disclosure Statement**

The authors declare no conflict of interest.

**References**